Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Trastuzumab Emtansine Plus Atezolizumab in Previously Treated, HER2-Positive Advanced Breast Cancer
- Real-World Study of Treatment for BRCA1/2 Mutated Advanced Breast Cancer
- Fulvestrant and Palbociclib as First-Line Treatment for HR+/HER2- Breast Cancer
- ESMO 2020: Recommendations From Dr. Reshma Mahtani for Breast Cancer
- Talazoparib vs Chemotherapy in Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival in Patients With HR+, ERBB2− Metastatic Breast Cancer
- Cabazitaxel as Second-Line in Patients With HER2– Metastatic Breast Cancer Previously Treated With Taxanes
- Novel Therapies in the Management of HER2-Positive Breast Cancer
- T-DM1 in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastases
- Efficacy and Safety of T-DM1 + Capecitabine vs T-DM1 Alone in Previously Treated ERBB2+ Metastatic Breast Cancer